Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.

Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR, ICPC Investigators
Eur Heart J Cardiovasc Pharmacother. 2020 6 (4): 203-210

PMID: 31504375 · PMCID: PMC7363022 · DOI:10.1093/ehjcvp/pvz045

MeSH Terms (23)

Aged Brain Ischemia Clopidogrel Coronary Artery Disease Coronary Thrombosis Decision Support Techniques Europe Female Humans Male Middle Aged Myocardial Infarction Percutaneous Coronary Intervention Pharmacogenomic Variants Platelet Aggregation Platelet Aggregation Inhibitors Polymorphism, Single Nucleotide Predictive Value of Tests Risk Assessment Risk Factors Stents Stroke Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: